Inovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 … – Nasdaq
|
Inovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 …
Nasdaq The phase 1b/2 immuno-oncology trial will evaluate Genentech’s atezolizumab (TECENTRIQ®) in combination with Inovio’s INO-5401, a T cell activating immunotherapy encoding multiple antigens, and INO-9012, an immune activator encoding IL-12. BRIEF-Inovio announces clinical trial collaboration to evaluate t-cell immunotherapy in combination with a PD-l1 …Reuters |
Fast Company |
Unraveling The Controversy Over The CRISPR Mutations Study
Fast Company Cas9, the CRISPR enzyme that snips DNA, in contact with its target. [Graph: via rcsb.org] A central promise of CRISPR-based gene editing is its ability to pinpoint particular genes. But if this technology produces dangerous side effects by creating … A World First CRISPR Trial Will Edit Genes Inside the Human BodyFuturism One of Crispr’s Creators Faces Her FearsBloomberg From AAV to CRISPR: Era of hacking our bodies is just beginningSiliconrepublic.com Nature.com –Medical Xpress all 8 news articles » |
Bloomberg |
One of Crispr’s Creators Faces Her Fears – Bloomberg
Bloomberg In A Crack in Creation, Jennifer Doudna wrestles with her role in inventing the gene-editing tool and the implications of it. From AAV to CRISPR: Era of hacking our bodies is just beginningSiliconrepublic.com Genome editing: That’s the way the CRISPR crumbles : Nature …Nature.com A major step in treating genetic diseases – Medical XpressMedical Xpress |
PR Newswire (press release) |
Cancer Research Institute Hosts Fifth Annual Cancer Immunotherapy Month(tm) in June to Celebrate Progress in …
Newswise (press release) “Advances in immunotherapy research have brought us to a tipping point in the transformation of cancer treatment,” said Jill O’Donnell-Tormey, Ph.D., CEO and director of scientific affairs at the Cancer Research Institute. “But these advances have … Parker Institute for Cancer Immunotherapy Scientists to Present Research at ASCO 2017 on IDO Pathway Inhibitors …PR Newswire (press release) Gritstone Oncology Expands Scientific Advisory Board with Appointment of Immuno-Oncology Experts James L. Gulley …Business Wire (press release) ASCO 2017: World’s Largest Clinical Cancer Research Meeting to Highlight Latest Advances in Patient and Survivor …UroToday |
|
World-first trials have been launched to treat Parkinson’s and blindness with embryonic stem cells
ScienceAlert Meanwhile, another medical team in the same city is aiming to target vision loss using embryonic stem cells (ESC) to replace lost cells in the retina, marking a new direction in China in the wake of major changes in how the country regulates stem cell … |